Skip to main content

What type of lung cancer is Vizimpro used to treat?

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 8, 2023.

Official answer

by Drugs.com

Vizimpro by Pfizer is a daily oral medicine used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC).

It targets two specific cancer biomarkers detected by an FDA-approved test:

  • EGFR exon 19 deletion mutations
  • EGFR exon 21 L858R substitution mutations.

Other EGFR inhibitors that may be used in the treatment of NSCLC include:

References

Vizimpro Prescribing Information. Updated Oct 17, 2023. https://www.drugs.com/pro/vizimpro.html

Read next

Doxorubicin is considered one of the strongest chemotherapy drugs for breast cancer ever invented. It can kill cancer cells at every point in their life cycle, and it's used to treat a wide variety of cancers, not just breast cancer. Doxorubicin is also known as “The Red Devil” because it is a clear bright red color. It can cause your urine or other body fluids to turn a reddish color for 1 to 2 days after a dose is given, which is normal and temporary. Continue reading

Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading

A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer